A postdoctoral researcher at the University of Michigan won a three-year grant to support her work investigating the cellular mechanisms…
Articles by Lindsey Shapiro, PhD
Daily treatment with Ingrezza (valbenazine) led to reductions in motor- and cognitive-related disease burden for adults with chorea due…
uniQure plans to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) early next year…
Daily treatment with Ingrezza (valbenazine) eases the jerky, involuntary movements known as chorea across different body regions in…
One-year results from the Phase 2 PIVOT-HD clinical trial testing PTC Therapeutics’ Huntington’s disease treatment PTC518 are expected in…
While the vast majority of Huntington’s disease patients in North America have the uncontrolled and jerky movements known as…
Atalanta Therapeutics has raised $97 million to support planned Phase 1 clinical trials of its experimental RNA interference…
Subtle biomarkers of neurodegeneration are evident decades before the onset of overt Huntington’s disease symptoms in people with disease-causing…
Sage Therapeutics is discontinuing the development of dalzanemdor after the investigational therapy failed to improve cognitive abilities relative…
Alnylam Pharmaceuticals has launched a Phase 1 clinical trial to test the safety and pharmacological properties of its treatment candidate…